Sanofi (SNY) Stock Price Down 1%
Sanofi (NYSE:SNY) traded down 1% on Tuesday . The stock traded as low as $38.89 and last traded at $39.02, with a volume of 4,990,551 shares. The stock had previously closed at $39.40.
Several equities research analysts have recently weighed in on the stock. Citigroup Inc. reissued a “neutral” rating on shares of Sanofi in a research report on Wednesday, April 27th. Zacks Investment Research raised shares of Sanofi from a “hold” rating to a “buy” rating and set a $46.00 target price for the company in a research report on Wednesday, May 4th. HSBC lowered shares of Sanofi from a “buy” rating to a “hold” rating in a report on Tuesday, May 3rd. Bank of America Corp. reaffirmed a “buy” rating and issued a $58.00 price target on shares of Sanofi in a report on Tuesday, May 3rd. Finally, TheStreet raised shares of Sanofi from a “hold” rating to a “buy” rating in a report on Wednesday, July 27th. Four analysts have rated the stock with a sell rating, seven have given a hold rating and four have issued a buy rating to the stock. Sanofi has a consensus rating of “Hold” and an average target price of $60.50.
The company has a market capitalization of $99.58 billion and a P/E ratio of 21.203. The firm has a 50 day moving average price of $41.01 and a 200 day moving average price of $40.68.
Other institutional investors recently added to or reduced their stakes in the company. Rhumbline Advisers boosted its position in Sanofi by 7.3% in the fourth quarter. Rhumbline Advisers now owns 26,510 shares of the company’s stock valued at $1,131,000 after buying an additional 1,800 shares during the last quarter. BlackRock Advisors LLC boosted its position in Sanofi by 115.1% in the fourth quarter. BlackRock Advisors LLC now owns 695,109 shares of the company’s stock valued at $29,646,000 after buying an additional 372,000 shares during the last quarter. Finally, Stephens Inc. AR boosted its position in Sanofi by 4.5% in the fourth quarter. Stephens Inc. AR now owns 56,811 shares of the company’s stock valued at $2,423,000 after buying an additional 2,424 shares during the last quarter.
Sanofi SA is a healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. The Company is organized around three principal activities: Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial. The Company invests in emerging markets, diabetes solutions, vaccines, consumer health care, animal health, genzyme and other products.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.